[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methylene-blue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methylene-blue":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100605614","phase-4-efficacy-of-methylene-blue-plus-ropivacaine-for-post-hemorrhoidectomy-pain-100605614",false,"NCT07164807","Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain.","Comparative Efficacy of Varying Concentrations of Methylene Blue Combined With Ropivacaine for Postoperative Analgesia Following Milligan-Morgan Hemorrhoidectomy: A Single-Center, Prospective, Open-Label, Randomized, Parallel-Controlled Trial","Inclusion Criteria:\n\n1. Aged between 18 and 75 years.\n2. Diagnosed with Grade III-IV hemorrhoids according to the Goligher classification.\n3. Scheduled to undergo standard Milligan-Morgan hemorrhoidectomy.\n4. Procedure performed under spinal anesthesia alone.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Current immunotherapy or coagulopathies.\n3. Contraindications to any protocol-specified agents (e.g., history of severe allergic reactions to methylene blue or ropivacaine).\n4. Concurrent anorectal pathologies (e.g., perianal abscess, anal fistula, fecal incontinence).\n5. Comorbid systemic conditions (e.g., cardiac\u002Fhepatic\u002Frenal insufficiency, diabetes mellitus, coagulopathy, peptic ulcer disease).\n6. Incomplete perioperative documentation.\n7. Inability to comply with follow-up protocols.","ALL","18 Years","75 Years",{"count":20,"type":21},177,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Revised Translation (Academic English):\n\nAs one of the most prevalent anorectal disorders, mixed hemorrhoids continue to rely on the Milligan-Morgan hemorrhoidectomy as the gold-standard surgical approach. While this technique demonstrates well-established efficacy, managing acute postoperative pain-particularly during the critical 24-72-hour peak pain window-remains a persistent clinical challenge. Recent advancements in multimodal analgesia have highlighted the potential of local nerve blockers, with methylene blue (MB) gaining scientific interest due to its prolonged analgesic properties. This randomized controlled study systematically evaluates the synergistic analgesic effects of gradient concentrations of MB combined with ropivacaine (ROP) following Milligan-Morgan procedures. Therapeutic safety profiles were validated through dual-dimensional monitoring of Visual Analog Scale (VAS) scores and complication rates, aiming to establish evidence-based optimal dosing protocols and refine perioperative pain management strategies.",[27,28,29],"Mixed Hemorrhoids","Milligan-Morgan Hemorrhoidectomy","Methylene Blue","NOT_YET_RECRUITING","2025-09-08",{"date":33,"type":34},"2025-09-10","ACTUAL",{"date":36,"type":21},"2025-08-30",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"The Affiliated Hospital of Putian University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100503082","perineural-methylene-blue-infusion-in-lower-limb-amputation-surgery-100503082","NCT05830630","Perineural Methylene Blue Infusion in Lower Limb Amputation Surgery","The Preventive Value of Continuous Perineural Methylene Blue Infusion in Patients Undergoing Lower Limb Amputation Surgery","Inclusion Criteria:\n\n* Patients of both genders, suffering from vascular insufficiency of one or both lower limbs and scheduled for above or below knee amputation under general anesthesia.\n\nExclusion Criteria:\n\n* Patients with a history of allergy to local anesthetics.\n* Patients with allergy to methylene blue.\n* Anticoagulant use or coagulopathy.",true,{"count":52,"type":21},72,[54],"NA","This prospective randomized controlled study will be conducted to evaluate the analgesic effect of continuous perineural infusion of methylene blue with bupivacaine on acute postoperative pain and to evaluate its preventive role against chronic phantom pain in patients undergoing lower limb amputation surgery",[57,29,58],"Perineural","Lower Limb Amputation",[57,60,61],"Methylene blue","Lower limb amputation","RECRUITING","2025-07-04",{"date":65,"type":34},"2025-07-09",{"date":67,"type":34},"2023-05-01",{"date":69,"type":21},"2027-05-01",{"name":71,"class":41},"Tanta University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100553078","efficacy-and-safety-of-methylene-blue-in-the-treatment-of-severe-septic-shock-100553078","NCT06481410","Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock","Exploratory Study on the Efficacy and Safety of Methylene Blue in Treating Severe Septic Shock Patients: A Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Meets the Sepsis 3.0 criteria for septic shock: patients with infection who, despite adequate fluid resuscitation, require vasopressor therapy to maintain a mean arterial pressure (MAP) of ≥ 65 mmHg and have a blood lactate concentration \\> 2 mmol\u002FL.\n3. Diagnosed with septic shock and started on norepinephrine within 24 hours.\n4. Requires a norepinephrine dose of ≥ 0.1 μg\u002Fkg\u002Fmin to maintain a MAP of ≥ 65 mmHg.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Individuals allergic to methylene blue or any components of the methylene blue injection.\n3. Individuals with a personal or family history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n4. Patients with an expected survival time of less than 48 hours.\n5. Patients who have been on norepinephrine for more than 24 hours.",{"count":80,"type":21},488,[54],"The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.",[84,29,85],"Septic Shock","Sepsis",[84,60,85],"2024-12-26",{"date":89,"type":34},"2024-12-30",{"date":91,"type":34},"2024-06-22",{"date":93,"type":21},"2026-06-20",{"name":95,"class":41},"First Affiliated Hospital of Zhejiang University"]